Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma

Table 3 Univariable and multivariable models to predict grade 2 or higher adverse events

	Odds ratio	95%CI	P value
Univariable model:
PLR (> 300)	0.40	(0.16, 0.98)	0.044
NLR (> 5)	0.58	(0.31, 1.10)	0.097
Steroid use	2.74	(1.62, 4.64)	< 0.001
Antibiotics use	1.02	(0.52, 1.98)	0.954
Treatment
PD-1 CLTA-4	3	(1.35, 6.67)	0.007
PD-1 TKI	4	(1.71, 9.34)	0.001
Other1	4	(0.55, 28.97)	0.170
Multivariable model:
PLR (> 300)	0.26	(0.09, 0.74)	0.011
Steroid use	4.43	(2.21, 8.88)	< 0.001
Treatment
PD-1/CLTA-4	2.57	(1.06, 6.24)	0.037
PD-1/TKI	3.39	(1.34, 8.56)	0.01
Other1	3.50	(0.21, 57.86)	0.381

¹Other include single agent cytotoxic t-lymphocyte antigen-4 and other immune checkpoint inhibitors/tyrosine kinase inhibitor combinations. CI: Confidence interval; PLR: Platelet-lymphocyte ratio; NLR: Neutrophil-lymphocyte ratio; PD-1: Programmed cell death ligand 1; CLTA-4: Cytotoxic t-lymphocyte antigen-4; TKI: Tyrosine kinase inhibitor.